Last reviewed · How we verify
Different Antibiotic Combinations
Inonu University is developing various antibiotic combinations to address the growing issue of antibiotic resistance. These combinations aim to enhance efficacy and reduce the risk of resistance development by targeting multiple bacterial mechanisms simultaneously. The university's research focuses on innovative approaches to combat multidrug-resistant pathogens, which are a significant global health concern. Despite the promising preclinical results, these antibiotic combinations have not yet received FDA approval. Further clinical trials are necessary to establish their safety and efficacy in human patients.
At a glance
| Generic name | Different Antibiotic Combinations |
|---|---|
| Also known as | 3Mix-MP and Alternative 3Mix-MP |
| Sponsor | Inonu University |
| Drug class | Antibiotic combinations |
| Target | Multiple bacterial targets including cell wall synthesis, protein synthesis, and DNA replication |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Success of Lesion Sterilization and Tissue Repair Therapy (PHASE4)
- Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study (PHASE4)
- Comparative Evaluation of Antimicrobial Efficacy, Clinical and Radiographic Success of Calcium Hydroxide, Chlorhexidine, and Modified Triple Antibiotic Paste in Different Combination Forms As Intracanal Medicaments Against Enterococcus Faecalis in Primary Teeth (NA)
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia (PHASE3)
- Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis (PHASE4)
- Comparison of Three Different Antibiotic Treatments Against Recurrent Urinary Tract Infections in Catheterized Patients (NA)
- Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam (PHASE2)
- Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |